Fast-Tracking Biomarker Discovery into Clinical Research for Parkinson’s Disease
Access the Full Case Study from Dartmouth Geisel School of Medicine & Quanterix
Case Study
Developing reliable biomarker assays is essential for advancing Parkinson’s disease research and clinical translation. This case study details how Dr. Matthew Havrda’s team at Dartmouth’s Geisel School of Medicine, in collaboration with Quanterix, developed an ultra-sensitive NLRP3 assay to detect key markers of neuroinflammation.
Read the full case study to learn how:
- Dr. Matthew Havrda’s research team overcame assay sensitivity challenges
- Simoa technology enabled the detection of NLRP3 in previously undetectable samples
- Custom assay development accelerated biomarker translation for clinical research
Complete the form to download the full case study